gemfibrozil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1285 25812-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gemfibrosil
  • gemfibrozil
  • decrelip
  • lopizid
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
  • Molecular weight: 250.34
  • Formula: C15H22O3
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -3.95
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 79.89 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1981 FDA PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 462.50 40.47 124 344 46519 2311098
Rhabdomyolysis 345.68 40.47 69 399 6635 2350982
Completed suicide 162.88 40.47 47 421 20987 2336630
Drug interaction 115.08 40.47 39 429 29124 2328493
Myalgia 107.07 40.47 35 433 23298 2334319
Blood creatine phosphokinase increased 89.83 40.47 22 446 5114 2352503
Tendon rupture 56.19 40.47 12 456 1506 2356111
Myopathy 55.99 40.47 12 456 1531 2356086
Respiratory arrest 48.21 40.47 14 454 6164 2351453
Acute kidney injury 46.32 40.47 20 448 28102 2329515
Aspartate aminotransferase increased 45.99 40.47 16 452 12596 2345021
Alanine aminotransferase increased 44.32 40.47 16 452 14016 2343601

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 1224.93 47.41 249 505 10841 1735186
Acute kidney injury 475.12 47.41 149 605 34795 1711232
Blood creatine phosphokinase increased 300.72 47.41 78 676 8778 1737249
Drug hypersensitivity 290.23 47.41 85 669 15050 1730977
Myalgia 282.96 47.41 84 670 15574 1730453
Drug interaction 161.27 47.41 64 690 27894 1718133
Asthenia 115.67 47.41 54 700 34616 1711411
Blood triglycerides increased 102.59 47.41 26 728 2574 1743453
Completed suicide 92.25 47.41 37 717 16275 1729752
Myositis 83.23 47.41 20 734 1583 1744444
Blood cholesterol increased 79.79 47.41 22 732 3004 1743023
Muscular weakness 78.39 47.41 29 725 10220 1735807
Haemodialysis 78.21 47.41 21 733 2595 1743432
Myopathy 75.77 47.41 19 735 1794 1744233
Polymyositis 70.09 47.41 13 741 289 1745738
Aspartate aminotransferase increased 62.73 47.41 25 729 10731 1735296
Blood creatinine increased 59.72 47.41 26 728 13920 1732107
Alanine aminotransferase increased 56.19 47.41 24 730 12254 1733773
Hepatic enzyme increased 51.50 47.41 19 735 6602 1739425
Metabolic acidosis 51.40 47.41 18 736 5384 1740643
Chromaturia 50.62 47.41 15 739 2635 1743392

Pharmacologic Action:

SourceCodeDescription
ATC C10AB04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
FDA Chemical/Ingredient N0000170118 PPAR alpha
CHEBI has role CHEBI:35679 antilipemic drug
MeSH PA D000963 Antimetabolites
MeSH PA D065687 Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertriglyceridemia indication 302870006
Primary Prevention of Coronary Heart Disease indication
Hypoalphalipoproteinemia off-label use 190785000
Primary biliary cirrhosis contraindication 31712002 DOID:12236
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Leukopenia contraindication 84828003 DOID:615
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.13 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 4.23 IUPHAR CHEMBL
Cytochrome P450 2C8 Enzyme Ki 5.74 WOMBAT-PK
Lipoprotein lipase Enzyme WOMBAT-PK
Cytochrome P450 2C9 Enzyme Ki 4.52 WOMBAT-PK
Transthyretin Secreted Kd 7 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 5.73 CHEMBL

External reference:

IDSource
4018639 VUID
N0000146952 NUI
C0017245 UMLSCUI
D00334 KEGG_DRUG
35282000 SNOMEDCT_US
523 MMSL
4719 RXNORM
387189002 SNOMEDCT_US
4778 MMSL
d00245 MMSL
4018639 VANDF
002050 NDDF
CHEBI:5296 CHEBI
CHEMBL457 ChEMBL_ID
Q8X02027X3 UNII
3899 INN_ID
DB01241 DRUGBANK_ID
3463 PUBCHEM_CID
D015248 MESH_DESCRIPTOR_UI
3439 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lopid HUMAN PRESCRIPTION DRUG LABEL 1 0071-0737 TABLET, FILM COATED 600 mg ORAL NDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9130 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9707 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0615-3559 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 10544-569 TABLET, FILM COATED 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 16714-101 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 21695-732 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 24658-260 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 31722-225 TABLET 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 33261-146 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 42806-260 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 12 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-090 TABLET, FILM COATED 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-772 TABLET, FILM COATED 600 mg ORAL ANDA 13 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50090-2450 TABLET, FILM COATED 600 mg ORAL ANDA 10 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50090-2902 TABLET 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50268-350 TABLET 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51138-588 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-142 TABLET 600 mg ORAL ANDA 9 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53002-1068 TABLET 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53002-2068 TABLET, FILM COATED 600 mg ORAL ANDA 10 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53217-251 TABLET 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0251 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0368 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0673 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0838 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0863 TABLET, FILM COATED 600 mg ORAL ANDA 12 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 54868-2353 TABLET, FILM COATED 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 55700-493 TABLET 600 mg ORAL ANDA 11 sections